Tempus AI saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 78 to 85.
IBD's proprietary rating tracks share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
History reveals that the top-performing stocks typically have an RS Rating north of 80 as they begin their biggest price moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear an appropriate buy point.
Tempus AI showed 0% EPS growth last quarter, while sales growth came in at 33%.
The company earns the No. 23 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Catalent are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
